In the group of 216 safety reports in all, the four matching variables had the following characteristics: the median patient age was 68 years (interquartile range, IQR: 60–74 years); as to patient sex, 62.0% of the safety reports involved males; 59.3% of the patients had melanoma for their cancer type, and 69.4% received anti-PD-1/PD-L1 monotherapy for their ICI regimen. This evidence concerns the gene CD274 and cancer.